Genomic Antibody Technology™ can be used to generate mouse monoclonal
antibodies. Unlike conventional immunization techniques, Genomic
Technology™ eliminates the need for peptide or protein antigen. Your
protein amino acid sequence is analyzed for optimal antigen selection to
work is scheduled on predictable timelines. All activities requiring
attention such as project review appointment, sample ship dates, and
ship dates are scheduled at the beginning of the project. To determine
ELISA-positive monoclonal antibodies work in your applications, samples
candidate hybridomas are sent to your
further evaluation. Using data generated in our laboratories and data
in your laboratories, hybridomas secreting
useful hybridomas are identified.
Using this proprietary
immunization of mice for the development of monoclonal antibodies can
begin when the sequence of the protein antigen is known.
- You may have
determined the sequence in your laboratory or you may have taken the
sequence from public sources. The physical peptide or protein antigen
is not required.
- You provide only the protein sequence information of
the protein antigen.
- We build a plasmid containing sequence information
from your protein and transfer the plasmid into the host animals.
immunogen is expressed in vivo where it is immediately recognized
- Pre-immune and immune sera are evaluated by SDIX using
protein we express in the laboratory.
- Data from screening of sera and
hybridoma culture supernatant as well as samples of each are transferred
to you for further evaluation.
Receipt of target
protein sequence by email or through our website. Discuss desired use
of antibodies in your laboratories. Discuss
desired antibody performance characteristics. Up to 2 hours of
our scientific staff is included.
Immunization. Fifteen mice are
immunized using Genomic Antibody Technology™.
Screening. Sera are collected at the end of
the immunization protocol. The sera are tested at SDIX by ELISA using
generated by SDIX. The sera and the data generated at SDIX are sent to the
customer for evaluation and review.
Project Review. After you have
reviewed SDIX’s data and after you have
evaluated the sera in your laboratories, the project status is discussed
PHASE I TIMING: 82 days (~12 weeks).
Phase II: Cell Fusion, Screening, Cloning,
Select Mice for Fusion. Using data
generated by SDIX and data generated in your
laboratories, three mice are identified for fusion with myeloma cell
Screening. After fusion, culture
supernatants are screened by ELISA using
antigen generated by SDIX. Up to 30 supernatant samples are sent to you
evaluation. Of these, six are selected by you for freezing.
Cloning. Of the six selected for
freezing, three are selected by you for limiting dilution cloning to
insure monoclonality. A five vial freeze is
made of the six selected and a ten vial freeze is made of
each subclone selected.
Freezing and Cloning. Positive hybridomas are cloned and cryopreserved.
lines are dispersed at your direction.
Storage or Shipment. At your direction, cryopreserved hybridomas
and clones are stored at SDIX for one year free
of charge or shipped to you.
Antibody Production. The cloned hybridoma cell lines can be
used to make purified antibody by choosing from SDIX’s production and
purification options (not included in this phase).
PHASE II TIMING: 87 days (~12 weeks)
from fusion to shipment of storage/shipment
TOTAL HYBRIDOMA DEVELOPMENT TIMING: 169 days (~24
Phase III - R&D
Small-scale Production (in vivo or in vitro)
and Purification A 10 mouse ascites run with
(5 weeks) or 3.0 L roller bottle run with Protein A
purification (3 weeks); using a subclone developed during Phase II Hybridoma Development.
Additional supernatant from PII fusion candidates
Additional parental from PII supernatants
Additional subclone of a PII
parental In Vivo and In Vitro
Monoclonal Purification Services
Conjugation and Fragmentation Services
Cell Banking Services and Storage
Hybridoma Development is also
available using traditional protein or peptide immunization.
Hybridoma development is
client exclusively owns the monoclonal antibodies and hybridoma
cell lines developed during the project.
research use only.